0001104659-23-127783.txt : 20231220 0001104659-23-127783.hdr.sgml : 20231220 20231220171618 ACCESSION NUMBER: 0001104659-23-127783 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231220 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231220 DATE AS OF CHANGE: 20231220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Liquidia Corp CENTRAL INDEX KEY: 0001819576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851710962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39724 FILM NUMBER: 231502148 BUSINESS ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919.328.4400 MAIL ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 8-K 1 tm2333396d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 20, 2023

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	001-39724	85-1710962
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


419 Davis Drive, Suite 100, Morrisville, North Carolina		27560
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (919) 328-4400

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock	LQDA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 8.01 Other Events.

As previously disclosed, in January 2021, Liquidia Corporation, a Delaware Corporation (the “Company”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) for inter partes review of U.S. Patent No. 10,716,793 (the “’793 Patent”), seeking a determination that the claims in the ‘793 Patent are invalid. In July 2022, the PTAB ruled in our favor, concluding that based on the preponderance of the evidence, all the claims of the ’793 Patent have been shown to be unpatentable due to the existence of prior art cited by the Company in the inter partes review proceedings. In August 2022, United Therapeutics Corporation (“United Therapeutics”) submitted a rehearing request with respect to the PTAB’s decision in the inter partes review of the ‘793 Patent. The rehearing request was denied in February 2023. In April 2023, United Therapeutics appealed the decision of the PTAB with respect to the ‘793 Patent to the United States Court of Appeals for the Federal Circuit. Oral argument on the appeal was held on December 4, 2023.

On December 20, 2023, the Company issued a press release announcing that the United States Court of Appeals for the Federal Circuit affirmed the earlier decision of the PTAB. As a result of the decision, the Company will immediately seek to set aside the injunction issued by the U.S. District Court for the District of Delaware in the lawsuit filed by United Therapeutics under the Drug Price Competition and Patent Term Restoration Act (the “Hatch-Waxman Act”) and pursue final regulatory approval of YUTREPIA by the U.S. Food and Drug Administration.

A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Exhibit
99.1		Press Release of Liquidia Corporation, dated December 20, 2023.
104		Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

December 20, 2023	Liquidia Corporation

	By:	/s/ Michael Kaseta
		Name: Michael Kaseta
		Title: Chief Financial Officer

EX-99.1 2 tm2333396d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)

-

Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalation

-

Liquidia will immediately request that District Court set aside injunction tied to ‘793 patent

MORRISVILLE, N.C., December 20, 2023 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) today affirmed the earlier decision by the Patent Trial and Appeal Board (PTAB) which found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) to be unpatentable due to the existence of prior art cited by Liquidia in inter partes review (IPR) proceedings. As a result of today’s decision, Liquidia will immediately seek to set aside the injunction issued by the U.S. District Court for the District of Delaware (District Court) in the lawsuit filed by United Therapeutics (UTHR) under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) and pursue final regulatory approval of YUTREPIA by the U.S. Food and Drug Administration (FDA).

Roger Jeffs, Chief Executive Officer of Liquidia, stated: “We are thrilled with the court’s swift decision. We now have rulings from the Federal Circuit confirming that YUTREPIA does not infringe any valid claim in any of the three patents that were initially asserted by United Therapeutics. We will now direct our attention towards the more important goal of improving patients’ lives and addressing unmet needs by seeking final FDA approval of YUTREPIA to treat PAH and, subsequently, PH-ILD.”

As a result of today’s decision, Liquidia will also seek to dismiss all claims related to the ‘793 patent in the second Hatch-Waxman lawsuit filed by UTHR in association with Liquidia’s amended New Drug Application (NDA) to add the indication to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD) to the YUTREPIA label. On November 30, 2023, UTHR filed an amended complaint in Hatch-Waxman litigation adding allegations that the Company infringes a newly issued patent, U.S. Patent No. 11,826,327 (’327 Patent). Because neither the ’793 Patent nor the ’327 Patent was issued prior to the filing of the original NDA for YUTREPIA, the Company believes UTHR is not entitled to a statutory 30-month stay with respect to either of these patents. The Company intends to vigorously defend itself against these allegations, so that patients suffering from PAH and PH-ILD can have the potential to access the Company’s products.

The FDA tentatively approved YUTREPIA to treat pulmonary arterial hypertension (PAH) in November 2021. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of January 24, 2024, for the PH-ILD indication.

About YUTREPIA™(treprostinil) inhalation powder

YUTREPIA is an investigational, inhaled dry powder formulation of treprostinil delivered through a convenient, low-resistance, palm-sized device. On November 5, 2021, the FDA issued a tentative approval for YUTREPIA for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. In July 2023, Liquidia filed an amendment to its NDA for YUTREPIA, seeking to add pulmonary hypertension with interstitial lung disease (PH-ILD) to the label. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of January 24, 2024 for the amendment. Previously, the FDA has confirmed that YUTREPIA may add the treatment of PH-ILD to the label for YUTREPIA without additional clinical studies. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape, and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA was previously referred to as LIQ861 in investigational studies.

About pulmonary arterial hypertension (PAH)

Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Currently, an estimated 45,000 patients are diagnosed and treated in the United States. There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression, and improve quality of life.

About pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) includes a diverse collection of up to 150 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease related ILD, and chronic pulmonary fibrosis with emphysema (CPFE) among others. Any level of PH in ILD patients is associated with poor 3-year survival. A current estimate of PH-ILD prevalence in the United States is greater than 60,000 patients, though population growth in many of these underlying ILD diseases is not yet known due to factors including underdiagnosis and lack of approved treatments until March 2021, when inhaled treprostinil was first approved for this indication.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia Technologies is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America. Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

Tyvaso^® is a registered trademark of United Therapeutics Corporation.

Cautionary Statements Regarding Forward-Looking Statements

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, including the potential for final FDA approval of the NDA for YUTREPIA, the timeline or outcome related to patent litigation in the U.S. District Court for the District of Delaware or inter partes review proceedings conducted at the PTAB, including appeals of decisions in any such proceedings, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The favorable decisions of the PTAB with respect to the ’793 patent is not determinative of the outcome of the appeal of the decision. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, including the impact of the coronavirus (COVID-19) outbreak on our Company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Media & Investors:

Jason Adair
Chief Business Officer

919.328.4400
jason.adair@liquidia.com

EX-101.SCH 3 lqda-20231220.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lqda-20231220_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lqda-20231220_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 20, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 20, 2023
Entity File Number	001-39724
Entity Registrant Name	LIQUIDIA CORPORATION
Entity Central Index Key	0001819576
Entity Tax Identification Number	85-1710962
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	419 Davis Drive
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Morrisville
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27560
City Area Code	919
Local Phone Number	328-4400
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock
Trading Symbol	LQDA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true

XML 7 tm2333396d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001819576 2023-12-20 2023-12-20 iso4217:USD shares iso4217:USD shares false 0001819576 8-K 2023-12-20 LIQUIDIA CORPORATION DE 001-39724 85-1710962 419 Davis Drive Suite 100 Morrisville NC 27560 919 328-4400 false false false false Common stock LQDA NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://liquidia.com/role/Cover Cover Cover 1 false false All Reports Book All Reports lqda-20231220.xsd lqda-20231220_lab.xml lqda-20231220_pre.xml tm2333396d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333396d1_8k.htm": { "nsprefix": "lqda", "nsuri": "http://liquidia.com/20231220", "dts": { "schema": { "local": [ "lqda-20231220.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lqda-20231220_lab.xml" ] }, "presentationLink": { "local": [ "lqda-20231220_pre.xml" ] }, "inline": { "local": [ "tm2333396d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://liquidia.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333396d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333396d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-23-127783-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-127783-xbrl.zip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end